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Abstract 
It was shown that osteopontin (OPN), a glycophosphoprotein, plays divergent roles in cancer 
progression. In addition to multiple intra- and extracellular functions, it facilitates migration 
of tumor cells, has crucial role in cell adhesion and is associated with increased metastasis 
formation. In previous studies, we performed global gene-expression profiling on a series of 
primary melanoma samples and found that OPN was significantly overexpressed in ulcerated 
melanomas. The major purpose of this study was to define OPN expression in primary 
melanomas with differing biological behaviours. OPN mRNA expression was analysed by 
quantitative reverse transcription polymerase chain reaction (qRT-PCR) in primary melanoma 
tissues. Immunohistochemistry was performed using a tissue microarray. Cox regression tests 
were used for survival analysis. Greater than 50% of the tissues exhibited high protein 
expression that was significantly associated with tumor thickness and metastasis. OPN mRNA 
expression was significantly increased in thicker melanomas and lesions with an ulcerated 
surface. Increased expression was primarily detected in advanced-stage tumors. A 
multivariate Cox regression analysis revealed that high OPN expression, tumor thickness, and 
metastasis were significantly associated with reduced relapse-free survival. In summary, high 
OPN mRNA and protein expression were associated with a less favourable clinical outcome 
of primary melanoma patients. We determined that OPN is a significant predictive factor for 
the survival of primary melanoma patients. Based on our and others data the high expression 
of OPN may have a crucial stimulatory role in tumor progression and metastasis formation, 
thus, have been proposed as potential targets for cancer diagnosis and therapy.  
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Introduction 
Malignant melanoma is the most aggressive type of skin cancer, with rapidly increasing 
incidence worldwide [1-3]. Despite previous intensive research to advance our 
understanding of melanoma progression, therapeutic options remain limited, and 
melanoma is mainly cured surgically [4, 5]. New therapeutic targets and diagnostic 
tools are especially warranted.  
Osteopontin (OPN) is a multifunctional extracellular matrix protein that is produced by 
numerous cell types [6-11]. OPN plays important roles in cancer cell adhesion, cell 
motility, and survival [12-16]. Previous reports indicated that the OPN is a crucial 
participant in the regulation of cancer cell signalling, ultimately leading to tumor 
progression [17-22]. 
Several studies indicate that OPN protein is overexpressed in the majority of human 
cancers, including malignant melanoma, and is associated with tumor progression [14, 
23-30]. Extensive microarray analyses of melanomas demonstrated that OPN also plays 
a role in melanoma progression [14, 28, 31, 32]. 
Several research groups have studied OPN expression at both the protein and mRNA 
levels in primary and metastatic melanomas and demonstrated that OPN expression is 
significantly increased in melanoma samples compared with naevi [14, 28, 31]. One of 
these studies did not identify an association between protein expression level and the 
clinicopathological parameters of primary melanoma tumors [14]. Other studies have 
reported that OPN was significantly overexpressed in primary and metastatic 
melanomas, but none of these studies reported an unequivocal correlation among OPN 
expression levels and the primary melanoma thickness, stage, and relapse-free survival 
[24]. According to the majority of the studies, OPN is a specific tumor marker 
candidate; therefore, OPN might serve as a potential target for therapeutic intervention 
to control melanoma progression [24, 33, 34]. However, the prognostic relevance of 
OPN in melanoma has not been fully elucidated. 
In previous studies, we performed global gene-expression profiling on a series of 
primary melanoma samples and report that OPN was significantly associated with poor 
clinical outcome [35]. In this study, our aim was to confirm our previous microarray 
data; furthermore, we sought to elucidate OPN expression at both the mRNA and 
protein levels in primary melanoma samples using quantitative polymerase chain 
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reaction (PCR), tissue microarray, and immunohistochemistry. To characterise the 
clinical parameters that might impact molecular alterations, we also aimed to define the 
association between OPN expression and the clinicopathological parameters of 
melanoma patients. Furthermore, we analysed the relationship between OPN expression 
and melanoma patient survival. 
  
Material and Methods 
Melanoma tissue samples 
Melanoma tissues were obtained from the Department of Dermatology, University of 
Debrecen, Hungary. This study was approved by the Regional and Institutional Ethics 
Committee of the University of Debrecen Clinical Center and performed according to 
the relevant regulations. Written informed consent was obtained from the patients. 
Lesions were diagnosed based on formalin-fixed paraffin-embedded (FFPE) tissue 
sections that were stained with haematoxylin-eosin (H&E). A total of 93 tumors were 
examined using immunohistochemistry, 28 tumors were analysed by real-time 
quantitative reverse transcription polymerase chain reaction (qRT–PCR), and 14 tumors 
were analysed using both methods. The clinicopathological data of the primary 
melanomas are summarised in Table 1. 
RNA extraction and qRT-PCR 
The RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) was used to isolate the total 
RNA from 28 fresh melanoma tissues according to the manufacturer’s protocol. The 
quantities of the RNA samples were determined using a NanoDrop ND-1000 UV-Vis 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Reverse 
transcription (RT) was performed on total RNA (600 ng) using the High-Capacity 
cDNA Reverse Transcription Kit according to the manufacturer’s protocol (Life 
Technologies Corporation, Carlsbad, California, USA). TaqMan one-step RT-PCR was 
used to determine the mRNA level of the OPN gene. Each reaction contained 150 ng of 
total sample RNA, and the reactions were run in triplicate on an ABI-PRISM 7000 
instrument (Applied Biosystems, Carlsbad, CA, USA). PCR Master Mix and assays 
(Hs00167093_m1 OPN targeting the exon 3-4 boundary) were obtained from Life 
Technologies. PCR data were analysed using the Livak method (2
-ΔΔCt
) using 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Hs99999905_m1) and beta-actin 
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(ACTB; Hs99999903_m1) as the reference (endogenous controls) genes and naevi as 
the calibrator sample [36]. 
Tissue microarrays and immunohistochemistry 
A total of 93 FFPE melanomas were included in the tissue microarray analysis (TMA) 
[37]. The clinicopathological data of the primary melanomas are summarised in Table 1. 
Tissue sections (4 μm) of the original blocks were first stained with H&E and then 
reviewed by pathologists to select the area to be punched automatically using the TMA 
Master (Carl Zeiss, Jena, Germany). We used triplicate 1-mm tumor cores from each 
donor block. Serial sections of 4 μm were excised from the TMA blocks and used for 
immunohistochemical investigations following H&E validation of the sample spots. 
After deparaffinisation and blocking the endogenous peroxidases (1% H2O2 for 10 min 
at RT) and non-specific binding sites, we retrieved antigens in 1 mM boiling citrate 
buffer (pH 6, 3 min). Then, the primary antibody, rabbit polyclonal anti-osteopontin 
IgG (Thermo Scientific, USA), was added at a 1:20 dilution and incubated for 1 h at 
room temperature (RT). After incubation with the primary antibody, the samples were 
stained using the Envision detection system (DAKO Inc., Carpinteria, CA, USA) and 
the VIP Peroxidase Substrate Kit (Vector Laboratories LTD, Peterborough, UK). The 
nuclei were counterstained with methyl green (Vector Laboratories LTD, Peterborough, 
UK). The primary antibody was omitted in negative controls. The HeLa cervical cancer 
cell line was used as a positive control. The slides were digitised using the MiraxScan 
slide scanning device (Carl Zeiss, Jena, Germany) as previously described [38]. Digital 
images were displayed using MiraxViewer software (Carl Zeiss, Jena, Germany) and 
evaluated by two dermatopathologists who were blind with respect to the sample data. 
We determined the tumor cell proportion score and intensity score. The proportion score 
included the fraction of positively stained tumor cells as follows: 0 = none, 1+ = < 5%, 
2+ = 5-50%, and 3+ = > 50%. The estimated average staining intensity of the positive 
tumor cells was expressed as follows: 0 = none, 1+ = weak, 2+ = moderate, and 3+ = 
strong (Figure 1). 
Statistical analysis 
SPSS (Statistical Package for the Social Sciences) 22.0 software (SPSS Inc., Chicago, 
IL, USA) was used for statistical analysis. Fisher’s exact and Mann-Whitney-Wilcoxon 
tests were used to compare OPN expression and clinicopathological data of the primary 
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tumors. To analyse the relationship between qRT-PCR data and clinicopathological 
parameters of melanoma patients, we used Mann-Whitney-Wilcoxon tests. Fisher’s 
exact test was performed for the statistical analysis of protein expression data. The 
predictors of survival were evaluated with a Cox regression analysis. Survival times 
were calculated as the time from diagnosis to the last follow-up or death. Logistic 
regression was used to analyse the association between prognostic factors and the 
formation of metastasis. A p value < 0.05 was considered statistically significant. 
 
Results 
OPN mRNA expression in primary melanomas 
OPN gene expression analysis was performed in 28 primary melanomas. A greater than 
two-fold increase in the OPN mRNA level was found in 93% (26/28) of these 
melanomas. We determined the relationship between gene expression levels and 
clinicopathological parameters. OPN mRNA expression was significantly increased in 
thicker melanomas (greater than 4.00 mm) and ulcerated lesions; furthermore, OPN was 
present mainly in late-stage tumors (Clark levels IV and V) (Figure 2). 
Fourteen overlapping samples were used to compare the gene- and protein-expression 
levels in the same tumor samples (Table 2). Increased OPN mRNA expression levels 
were detected in the majority of primary melanoma samples and were associated with 
different degrees of protein expression. A few contradictions may result from the fact 
that the samples used for the qRT-PCR and immunohistochemical study were derived 
from a part of the tumor that exhibits significant normal cell contamination. We did not 
observe any correlation between OPN protein levels and mRNA expression. 
Association between OPN protein expression and clinicopathological 
characteristics in primary melanomas 
We examined OPN protein expression levels in 93 primary melanomas. In total, 87% 
(81/93) of the melanoma samples were positive for OPN. The remaining 12 samples 
showed no OPN positivity. Greater than 50% of primary melanomas with poor clinical 
outcome exhibited increased OPN protein expression. Primary lesions in which at least 
50% of the tumor cells showed  high OPN expression were associated with 
unfavourable prognosis (nodular subtype, advanced stage, > 4.01 mm thickness, 
ulcerated surface, metastasis formation, and < 5-year survival). OPN positivity 
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exhibited a significant correlation with Breslow tumor thickness and metastasis (p = 
0.021 and p = 0.036, respectively, Table 3). Melanoma samples with poor clinical 
outcome showed stronger OPN staining. We analysed the relationship between OPN 
expression levels and clinicopathological data of the primary tumors. Increased OPN 
expression was significantly associated with increasing tumor thickness (p = 0.007, 
proportion of tumor cells and Breslow thickness; p = 0.033, staining intensity and 
Breslow thickness). We assessed the effect of OPN expression and prognostic factors on 
metastasis formation using multivariate logistic regression analyses. These results 
indicate that melanomas with OPN expression exhibited a 1.39-fold increased risk of 
metastasis, but this association was not significant (p = 0.691). However, Breslow 
thickness (p = 0.032) and ulceration (p = 0.002) were significantly associated with 
metastasis (Table 4). 
Multivariate Cox regression analyses of survival were performed regarding OPN 
expression levels and various prognostic factors such as ulceration, Breslow thickness 
and metastatic potential. In this analysis, we demonstrated that high OPN expression 
(score of 2 or 3) [hazard ratio (HR)=2.02; 95% confidence interval (CI)=0.99-4.14; 
p=0.050], tumor thickness [HR=1.66; 95% CI=1.01-2.74; p=0.046], and metastasis 
[HR=14.25; 95% CI=4.98-40.77; p<0.001] were significantly associated with reduced 
melanoma patient survival. 
 
Discussion 
In the last decade, several studies have defined the important role of OPN in 
tumorigenesis and metastasis. In human malignant melanoma, OPN expression is 
significantly associated with reduced relapse-free survival and additional histological 
parameters that are associated with poor clinical outcome [7, 24, 29, 33]. OPN is a 
prognostic marker in a variety of cancers [30, 39-41]. In metastatic and primary 
melanomas, OPN has also been suggested to be a novel promising biomarker for the 
detection of metastases in patients with primary melanomas [24, 42-45]. Atai et al. 
performed a meta-analysis across several distinct cancer microarray data sets and found 
increased OPN gene expression in at least 90% of melanoma patients[46]. 
Our group recently published a comprehensive microarray analysis in primary 
melanomas and reported that increased OPN mRNA expression in melanomas is 
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characteristic of less-favourable clinical outcomes [35]. Our present study successfully 
validated the aforementioned microarray results by qRT-PCR, revealing that increased 
OPN mRNA expression is significantly associated with later-stage melanomas (Clark 
levels IV-V) with an ulcerated surface and higher thickness (greater than 4.00 mm). 
Previous studies have reported that increased OPN mRNA expression is associated with 
unfavourable patient prognosis in human cancers, including melanoma [9, 29]. In 
addition, we extended our studies to OPN protein levels and therefore fabricated tissue 
microarray platforms for 93 primary melanomas. By performing immunohistochemistry 
on the primary melanoma specimens, we observed increased OPN protein levels in 
samples with poor prognosis. Notably, increasing immunostaining was significantly 
associated with Breslow tumor thickness and metastatic capacity, indicating a role for 
OPN in melanoma progression [7, 24]. However, our protein and gene expression 
results did not reveal clear relationships in all samples, and on average, we observed 
that increased OPN mRNA levels were associated with strong antigen positivity. The 
main reason for this phenomenon might be due to the relatively limited number of 
melanoma specimens. Several previous studies have simultaneously investigated OPN 
mRNA and protein expression in various cancers, including melanoma, and found that 
OPN was overexpressed in tumors that were associated with less favourable prognoses 
[9, 28, 31, 32]. A logistic regression analysis revealed increased metastasis in thicker 
melanomas [odds ratio (OR) = 3.11; 95% confidence interval (CI) = 1.10-8.75; 
p=0.032] and ulcerated lesions (OR = 5.47; 95% CI = 1.85-16.17; p = 0.002). In a 
multivariate Cox regression analysis, increased OPN expression emerged as a predictor 
of survival after thickness and metastasis. Patients with increased OPN expression (a 
score of 2 or 3) exhibited a 2.02-fold increased risk of death from disease (p = 0.050), 
which is consistent with that described in the literature [15, 24]. Elevated OPN 
expression is associated with advanced stage, tumor invasion, and metastasis in multiple 
cancers. The function of OPN is versatile and involves the induction of multiple 
signalling pathways (PI 3’-kinase/Akt, NF-kB) by integrin and CD44 receptors that 
mediate metastatic processes [8, 18, 19]. 
In summary, we demonstrate that tumor OPN expression is a strong predictor of poor 
prognosis.  A multivariate analysis confirmed that OPN is a significant predictive factor 
for primary melanoma patient survival. This study provides further evidence regarding 
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the importance of OPN in the biology of melanoma. Our findings are consistent with 
those of previous studies and support the hypothesis that OPN expression is a potential 
biomarker of melanoma progression [29, 33]. 
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Figure legends 
 
Figure 1. Scoring system for immunostaining intensity of primary melanoma 
tissues. The staining intensity of OPN in melanoma samples with no / 0 (a), weak / 1+ 
(b), medium / 2+ (c) and high / 3+ (d) level protein expression. 
 
Figure 2. Log2 - transformed OPN mRNA levels in melanomas relative to control 
naevus. Significant difference between clinical-pathological parameters and gene 
expression levels. The mRNA expression of OPN was significantly higher in late stage 
melanomas with ulcerated tumor surface and higher thickness. 
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